Promotions & Moves

Anchiano Therapeutics Names CMO

Kerstein to lead development of DNA-based cancer therapy to treat malignancies in the urinary bladder

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

David Kerstein, M.D., has been named chief medical officer of Anchiano Therapeutics, a clinical-stage biopharma company focused on novel therapies to treat cancer. Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies. “We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,” said Frank Haluska, president and chief executive officer of Anchiano Therapeutics....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters